GU Cancers 2025 | Challenges in managing and diagnosing low-PSA, high-risk prostate cancer

Goutam Chakraborty • 13 Feb 2025

GU Cancers 2025

Goutam Chakraborty, PhD, Icahn School of Medicine at Mount Sinai, New York, NY, comments on the challenges of diagnosing low-PSA, high-risk prostate cancer, noting that the lack of expression of prostate-specific antigen (PSA) makes it difficult to detect through biopsy alone. Dr Chakraborty emphasizes the need for a better biomarker to identify this subtype of prostate cancer, which often presents with advanced symptoms such as bone pain, and highlights the importance of preclinical studies to better understand this aggressive form of the disease. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.